Clinical Study
Prediction of Early Response to Chemotherapy in Lung Cancer by Using Diffusion-Weighted MR Imaging

Jing Yu,1 Weidong Li,2 Zhang Zhang,1 Tielian Yu,1 and Dong Li1

1 Department of Radiology, Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin 300052, China
2 Department of Radiology, Affiliated Hospital of Xuzhou Medical College, No. 99, Huaihaixilu, Quanshan District, Xuzhou 221002, China

Correspondence should be addressed to Dong Li; lidong53077@163.com

Received 10 December 2013; Accepted 29 December 2013; Published 12 February 2014

Academic Editors: D. Isla and Y. Ni

Copyright © 2014 Jing Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To determine whether change of apparent diffusion coefficient (ADC) value could predict early response to chemotherapy in lung cancer. Materials and Methods. Twenty-five patients with advanced non-small cell lung cancer underwent chest MR imaging including DWI before and at the end of the first cycle of chemotherapy. The tumor’s mean ADC value and diameters on MR images were calculated and compared. The grouping reference was based on serial CT scans according to Response Evaluation Criteria in Solid Tumors. Logistic regression was applied to assess treatment response prediction ability of ADC value and diameters. Results. The change of ADC value in partial response group was higher than that in stable disease group ($P = 0.004$). ROC curve showed that ADC value could predict treatment response with 100% sensitivity, 64.71% specificity, 57.14% positive predictive value, 100% negative predictive value, and 82.7% accuracy. The area under the curve for combination of ADC value and longest diameter change was higher than any parameter alone ($P \leq 0.01$). Conclusions. The change of ADC value may be a sensitive indicator to predict early response to chemotherapy in lung cancer. Prediction ability could be improved by combining the change of ADC value and longest diameter.

1. Introduction

Lung cancer is the most common and highly lethal cancer worldwide with poor prognosis [1]. About 75% of patients are diagnosed at advanced stage since there is no specific recognized symptom at early stage [2]. Surgery alone is not the appropriate treatment for those patients at terminal stage [3, 4]. A large meta-analysis pooled 4,584 patients suggested that the adjuvant chemotherapy had a 5.4% improvement of 5-year survival rate in non-small cell lung cancer [5].

Assessing the early response to chemotherapy in lung cancer is crucial because optimized chemotherapy regimen needs individualization to gain a preferable outcome and to avoid toxic effect and unnecessary expenditure. Currently, computed tomography (CT) and magnetic resonance (MR) imaging are the regular methods to monitor the tumor changes in size to evaluate the effect of chemotherapy [6]. However, response assessment with these morphologic imaging has limitations in reliable differentiation of residual tumor tissue from necrotic tumor or fibrotic scar. Moreover, the tumor change in size, which lags behind the biological and molecular changes, may be not an early and sensitive indicator [7].

MR diffusion-weighted imaging (DWI) reflects the differences in the Brownian motion of water molecules between tissues [8]. As a surrogate marker of tissue cellularity by observing water mobility within the tumor, the apparent diffusion coefficient (ADC) can be used to distinguish the highly cellular tumor from normal tissue or necrotic regions [8–10]. It has been used to differentiate pulmonary malignant tumors from solid benign lesions or to stage lung cancer [11, 12]. Therefore, the change of ADC value may be used to monitor the treatment response which manifested as change in cellularity of the tumor [8, 13]. Previous studies have demonstrated that ADC values can be used as an indicator to evaluate the tumor response in tumor from many organs [13–20]. The purpose of this study is to observe the change of ADC value after chemotherapy and to determine the ability...
of the change of ADC value to predict treatment response in lung cancer at the early stage of chemotherapy.

2. Materials and Methods

2.1. Patients. Research ethics committee approval and patient written informed consent were obtained. All the patients participated in the study were diagnosed as non-small cell lung cancers histologically. They were scheduled for chemotherapy and with no history of previous chemotherapy or other anticancer treatments. The patient selection was shown in the diagram (Figure 1). Finally, from 2010-12 to 2012-07, 25 patients (17 male, 8 female; median age: 61.4 ± 8.0 years) with advanced non-small cell lung cancers were consecutively enrolled. There were 2 patients with multiple lung lesions. Only the largest lung lesion was included in the MR image analysis. 14 squamous cell carcinomas, 9 adenocarcinomas, and 2 adenosquamous carcinomas were confirmed histologically. The initial staging protocol was evaluated by CT, MR, SPECT, and PET-CT if available. There were 23 stage III tumors and 2 stage IV tumor.

All patients underwent concurrent chemotherapy which consisted of gemcitabine or vinorelbine on days 1 and 8 and platinum-based pharmaceutical (75 mg/m²) for first 2 or 3 days in each 21-day cycle. The posttherapy MR imaging was performed at the end of the first cycle of chemotherapy. Patients remained on these treatment protocols until disease progression was detected.

2.2. MR. All patients accepted MR imaging one week before and after 1 cycle of chemotherapy (Figure 1). All the MR examinations were performed on a 3-T superconducting magnet (HDx; General Electric Medical Systems, Milwaukee, Wis) following the same protocol. Respiratory and electrocardiographically gated T2-weighted fast relaxation fast spin echo images with fat suppression images were obtained. The parameters were as follows: repetition time/echo time, 8,000–8,571 ms/86–96 ms; matrix size, 256 × 160; field of view, 42 cm; number of excitations, 2; slice thickness, 4 mm; gap, 1 mm. Electrocardiographically gated T1-weighted dual inversion recovery fast spin echo images were also obtained with the following parameters: repetition time/echo time, 1,120–1,760 ms/4.1–6.2 ms; matrix size, 256 × 160; field of view, 42 cm; number of excitations, 1; slice thickness, 4 mm; gap, 1 mm. These images were inspected initially to define locations of the pulmonary lesions for the DWI.

DWI were acquired using a respiratory gated single-shot echo-planar imaging sequence and array spatial sensitivity encoding technique with $b$ values of 0 and 1000 s/mm². The parameters were as follows: repetition time/echo time, 5,000–9,230 ms/55 ms; matrix size, 256 × 160; field of view, 42 cm; number of excitations, 4; slice thickness, 4 mm; gap, 1 mm; R factor, 2; slice-select, phase-encoding, and frequency-encoding directions. The total MR imaging acquisition time in this study was about 15 minutes.

2.3. Image Analysis. All MR images were transferred to a workstation (AW 4.3; GE Healthcare, Milwaukee, Wis) and analyzed by two experienced radiologists (A and B, 20 and 11 years experience in reading chest imaging, resp.), who were blinded to the therapeutic response and other data of patients. The following parameters were measured and

---

**Figure 1:** The patient selection and imaging flow chart. Baseline and follow-up CT are used for grouping.
recorded: lesion number, location, size, and mean ADC value. This procedure was performed by the two radiologists then the mean values were calculated.

The lesion size was reflected by tumor longest and shortest diameter (in perpendicular angle) measured with a caliper tool on axial T2-weighted images. The lesion location was observed on the T2- and T1-weighted images. Meanwhile, T2- and T1-weighted images were used as a slice selection reference for ADC value measurement.

During the MR image analysis, DWI reconstructed images with $b = 1000$ s/mm$^2$ were evaluated. The ADC map of each DWI image was produced on a pixel-by-pixel basis. An axial slice showing the largest tumor size corresponding to T2- and T1-weighted images was chosen. A polygonal region of interest was drawn manually encompassing the entire area of the target lesion on the ADC map (Figure 2). The mean ADC values were calculated.

2.4. CT Imaging. All patients underwent contrast enhanced CT scans before and after 2-3 cycles of chemotherapy conventionally (Figure 1) [21]. The images were obtained by using a 64-detector row CT (GE, light speed VCT XT) with a $64 \times 0.625$ mm collimation, 120 kVp, 250 mA, and 500 msec gantry rotation time in a spiral mode. The contrast enhanced CT images were acquired about 30 seconds after contrast material (Omnipaque 350, 90 mL) administration. The images were obtained in the transverse plane and then reconstructed by 2.5 mm section thickness and 2.5 mm section interval. One radiologist (C, 3 years experience in reading chest imaging), who was blinded to the results of MR images and other data of patients, measured the longest diameter of each tumor on the mediastinal window of CT images. Furthermore, the short diameters of lymph nodes (if lesions $\geq 15$ mm in short axis) will be recorded and included in the sum of lesions in calculation of the tumor response [22]. At last, the sum of the longest tumor diameters and shortest diameters of lymph nodes was calculated.

2.5. PR and SD Groups. According to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) [22, 23], the responses to chemotherapy in lung cancer were classified by B: (1) complete response: disappearance of all target lesions and reduction of any pathological lymph nodes ($<10$ mm in short diameter); (2) partial response (PR): at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; (3) stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; (4) progressive
Table 1: Patient and tumor characteristics between the PR and SD groups.

| Characteristics                     | PR (n = 8) | SD (n = 17) | P     |
|-------------------------------------|------------|-------------|-------|
| Age (years)                         | 66 (56–69) | 59 (56–66)  | 0.587 |
| Female/male                         | 1/7        | 7/10        | 0.205 |
| Smoker                              | 4          | 9           | 0.891 |
| Lesion location                     |            |             | 0.389 |
| Right lobe                          | 3          | 11          |       |
| Left lobe                           | 5          | 6           |       |
| Histological subtype                |            |             | 0.089 |
| Squamous cell carcinomas            | 7          | 7           |       |
| Adenocarcinomas                     | 1          | 8           |       |
| Adenosquamous carcinomas            | 0          | 2           |       |
| Stage                               |            |             | 0.456 |
| III A                               | 3          | 8           |       |
| III B                               | 5          | 7           |       |
| IV                                  | 0          | 2           |       |
| ADC at baseline (10⁻³ mm²/s)        | 1.26 ± 0.17| 1.20 ± 0.20 | 0.517 |
| Change of longest diameter (cm)     | 1.76 ± 0.92| 0.61 ± 0.88 | 0.007 |
| Change of shortest diameter (cm)    | 1.11 ± 0.11| 0.37 ± 0.66 | 0.045 |
| Change of ADC value (10⁻³ mm²/s)    | 0.90 ± 0.25| 0.37 ± 0.42 | 0.004 |

ADC: apparent diffusion coefficient; PR: partial response; SD: stable disease.

Table 2: Comparison of ADC values and different diameters before and after chemotherapy.

| Parameters                     | Pretherapy | Posttherapy | P     |
|-------------------------------|------------|-------------|-------|
| ADC (10⁻³ mm²/s)              | 1.22 ± 0.19| 1.76 ± 0.47 | 0.000 |
| Longest diameter (cm)         | 5.81 ± 2.18| 4.83 ± 2.11 | 0.000 |
| Shortest diameter (cm)        | 4.36 ± 1.65| 3.75 ± 1.84 | 0.002 |

ADC: apparent diffusion coefficient.

disease: at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on the study. Furthermore, a 5 mm absolute increase in sum of the target disease is needed. Based on the revised RECIST 1.1, the short diameters of lymph nodes (short diameter >15 mm) on axial CT images were included in the sum of target lesions in calculation of tumor response [23].

2.6. Statistical Analysis. Statistical analysis was performed using SPSS 17.0. Independent and paired student t-tests were used to analyze the difference of ADC value and tumor diameters between different groups or time periods. The frequencies of patient and tumor characteristics between PR and SD groups were tested by using X² test. To combine the changes of ADC value and diameter, a logistic regression model that allows the discrimination between PR and SD groups was employed. Receiver operator characteristic curves were generated to establish the cutoff value of the change of ADC value in order to differentiate PR lesion from SD lesion. A P value less than 0.05 was considered significant.

3. Results

In the current study, there were 8 and 17 patients in PR and SD group, respectively. No patient belonged to complete response or progressive disease group. The patient and tumor demographics between PR and SD groups was shown (Table 1).

Both longest and shortest diameter of the tumor had significant statistical differences before and after chemotherapy regardless in the SD or PR group (Table 2). The posttherapy ADC value was higher than pretherapy ADC value (P < 0.001) (Table 2).

When all tumors were divided into the PR and SD groups according to the mentioned criterion, it was noticed that the changes of tumor diameters on T2 images had significant difference between the SD and PR groups (P = 0.007 for longest diameter; P = 0.045 for shortest diameter) (Table 1). The pretherapy ADC value had no significant difference between the PR group and SD group (P = 0.517) (Table 1). The change of ADC value was statistically significantly higher in PR group compared with that in SD group (Table 1, Figure 3).

The logistic regression model and receiver operator characteristic curve analysis showed that combination of the change of longest diameter and ADC value had a higher area under curve than any other parameter alone for evaluating treatment response in lung cancer (P < 0.01, Figure 4). When we used the change of ADC value for differentiating the PR lesion from the SD lesion, the best cutoff value
Figure 3: The box plot showed that the change of apparent diffusion coefficient (ADC) value in partial response (PR) group were statistically significantly greater than that in stable disease (SD) group.

Figure 4: Compared with the change of apparent diffusion coefficient (ADC) value or tumor diameters alone, the combination of the change of ADC value and longest diameter (ADC & LD) had a higher area under the curve than any other alone for evaluating lung cancer treatment response (0.890, 0.827, and 0.838 for the combination, the change of ADC value, and longest diameter (LD), resp.).

4. Discussion

The chemotherapy response was usually observed after 2 cycles of chemotherapy according to tumor size change by radiographies, CT, or standard MR, rarely by functional imaging, dynamic or diffusion weighted MR imaging, or PET-CT, for example, [3, 6, 21, 24]. This study investigated whether the change of ADC value and diameters after chemotherapy could be used to evaluate early treatment response in lung cancer.

The ADC value had significant increase after 1 cycle of chemotherapy compared with baseline, especially in the PR group (Figure 3). This result was in agreement with the results of previous studies of both lung cancer and other cancers [17, 24–27]. However, the current result contradicted with the result of rectal cancer research on the decrease trend of ADC values 2–4 weeks after chemotherapy. Chemotherapy-induced fibrosis might be a contributor to decrease of ADC value [28]. The difference was probably caused by disparity in fibrosis appearance and progression. The increase of ADC value was related to necrosis and reduced cell density histologically [29], while the decrease of ADC value was relevant to cytotoxic edema and fibrosis on histology [28].

From the current results, the changes of ADC value were significant between the PR and SD groups (Table 1), which was in agreement with the previous DWI study of lung cancer treatment response evaluation after chemotherapy [24, 26], even when a different b value was used in the previous study [27]. Therefore, the noninvasive DWI could be potentially used to early predict and monitor lung cancer response to chemotherapy (Figure 2).

This study further demonstrated that the combination of longest diameter and ADC value change had a higher diagnostic ability than any other parameter alone for evaluating treatment response in lung cancer ($P < 0.01$, Figure 4). The receiver operator characteristic curve showed that the combination of longest diameter change and ADC value change adds additional value for a single parameter alone to predict treatment response. The cutoff value of ADC change could predict response to chemotherapy in lung cancer with 100% sensitivity, 64.71% specificity, 57.14% positive predictive value, 100% negative predictive value, and 82.7% accuracy.

Comparing with CT, the MR imaging had two benefits to evaluate tumor response: first, the DWI had the potential to evaluate early treatment response from the tumor inner structure change before the morphological change; second, by combining the change of ADC value and tumor diameter, the treatment response could be predicted with a high sensitivity and moderate specificity by using MR imaging only. For the small cell lung cancer, the tumor diameter change may be significant even in the early stage of chemotherapy. But for the less sensitive non-small cell lung cancer, especially on target therapy, there may not be apparent anatomical changes initially even if the chemotherapeutic regime was appropriate [29]. Therefore, tumor size evaluation alone had a smaller area under the curve than the combination of functional and anatomical assessment. The change of ADC value might have the potential to monitor and early predict lung cancer.
treatment response to chemotherapy. Furthermore, the diagnostic ability increased when combined with the change of ADC value and longest diameter. In our study, MR images at baseline and the end of 1 cycle of chemotherapy not only showed the tumor volume change on T2-weighted images, but also provided the change of ADC value on DWI. Even through MR imaging could not be regarded as the most appropriate and a "one stop" examination method to predict treatment response; it indeed provided precious information to CT.

There were several limitations of this study. Firstly, the sample number in our study was relatively small especially the pathological subtypes. Secondly, the tumor volume, pathologic types, and chemotherapy regimens were nonuniform, which may affect the treatment response of tumor. At last, the interval between the start of chemotherapy and treatment response evaluation by DWI was relatively long. One week interval may make the advantage of ADC value change prominent.

5. Conclusions

Our data suggested that the change of ADC value may be a sensitive indicator to predict early response to chemotherapy in lung cancer. Prediction ability could be improved by combining the change of ADC value and longest diameter.

Conflict of Interests

The authors declared that there was no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Rongchao Zhou for collecting part of patients. They appreciate the statistical suggestion from Ning-nannan Zhang. This study was supported by Tianjin Medical University Graduate Innovation Fund.

References

[1] E. F. Patz Jr., P. Pinsky, C. Gatsonis et al., "Overdiagnosis in low-dose computed tomography screening for lung cancer," JAMA Internal Medicine, vol. 12013, Article ID 12738, 6 pages, 2013.

[2] S. M. Smith, N. C. Campbell, U. MacLeod et al., "Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study," Thorax, vol. 64, no. 6, pp. 523–531, 2009.

[3] S. Gazala, J. S. Pelletier, D. Storie, J. A. Johnson, D. J. Kutzsogian-nis, and E. L. Bedard, "A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery," Scientific World Journal, vol. 2013, Article ID 789625, 2013.

[4] S. N. Sokucu, C. Kocaturk, N. Ucer et al., "Evaluation of six patients with pulmonary carcinoid tumors with a literature review," Scientific World Journal, vol. 2012, Article ID 167317, 2012.

[5] J.-P. Pignon, H. Tribodet, G. V. Scagliotti et al., "Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group," Journal of Clinical Oncology, vol. 26, no. 21, pp. 3552–3559, 2008.

[6] C. Suzuki, H. Jacobsson, T. Hatches et al., "Radiologic measurements of tumor response to treatment: practical approaches and limitations," Radiographics, vol. 28, no. 2, pp. 329–344, 2008.

[7] M. D. Pickles, P. Gibbs, M. Lowry, and L. W. Turnbull, "Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer," Magnetic Resonance Imaging, vol. 24, no. 7, pp. 843–847, 2006.

[8] D.-M. Koh and D. J. Collins, "Diffusion-weighted MRI in the body: applications and challenges in oncology," American Journal of Roentgenology, vol. 188, no. 6, pp. 1622–1635, 2007.

[9] H. Lyng, O. Haraldseth, and E. K. Rofstad, "Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging," Magnetic Resonance in Medicine, vol. 43, no. 6, pp. 828–836, 2000.

[10] Y. Zhang, J. Chen, J. Shen, J. Zhong, R. Ye, and B. Liang, "Apparent diffusion coefficient values of necrotic and solid portion of lymph nodes: differential diagnostic value in cervical lymphadenopathy," Clinical Radiology, vol. 68, no. 3, pp. 224–231, 2013.

[11] H. Liu, Y. Liu, T. Yu, and N. Ye, "Usefulness of diffusion-weighted MR imaging in the evaluation of pulmonary lesions," European Radiology, vol. 20, no. 4, pp. 807–815, 2010.

[12] S. Pauls, S. A. Schmidt, M. S. Juchems et al., "Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer," European Journal of Radiology, vol. 81, no. 1, pp. 178–182, 2012.

[13] Y. Cui, X.-P. Zhang, Y.-S. Sun, L. Tang, and L. Shen, "Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases," Radiology, vol. 248, no. 3, pp. 894–900, 2008.

[14] C. Messiou, D. J. Collins, S. Giles, J. S. de Bono, D. Bianchini, and N. M. de Souza, "Assessing response in bone metastases in prostate cancer with diffusion weighted MRI," European Radiology, vol. 21, no. 10, pp. 2169–2177, 2011.

[15] W. Reichardt, E. Juettner, M. Uhl, D. V. Elverfeldt, and U. Konnty, "Diffusion-weighted imaging as predictor of therapy response in an animal model of ewing sarcoma," Investigative Radiology, vol. 44, no. 5, pp. 298–303, 2009.

[16] M. Q. Huang, S. Pickup, D. S. Nelson et al., "Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI," NMR in Biomedicine, vol. 21, no. 10, pp. 1021–1029, 2008.

[17] M. Intven, O. Reerink, and M. E. Philippens, "Diffusion-weighted MRI in locally advanced rectal cancer: pathological response prediction after neo-adjuvant radiochemotherapy," Strahlenther Onkol, vol. 189, no. 2, pp. 117–122, 2012.

[18] J. H. Jensen and J. A. Helpern, "Progress in diffusion-weighted imaging: concepts, techniques and applications to the central nervous system," NMR in Biomedicine, vol. 23, no. 7, pp. 659–660, 2010.

[19] H. C. Thoeny, F. De Keyzer, F. Chen et al., "Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats," Radiology, vol. 248, no. 3, pp. 894–900, 2008.

[20] H. C. Thoeny, F. De Keyzer, F. Chen et al., "Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats," Radiology, vol. 248, no. 3, pp. 894–900, 2008.

[21] J. Wang, N. Wu, M. D. Cham, and Y. Song, "Tumor response in patients with advanced non-small cell lung cancer: perfusion
CT evaluation of chemotherapy and radiation therapy,” *American Journal of Roentgenology*, vol. 193, no. 4, pp. 1090–1096, 2009.

[22] M. Nishino, J. P. Jagannathan, N. H. Ramaiya, and A. D. Van den Abbeele, “Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know,” *American Journal of Roentgenology*, vol. 195, no. 2, pp. 281–289, 2010.

[23] E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” *European Journal of Cancer*, vol. 45, no. 2, pp. 228–247, 2009.

[24] H. Yabuuchi, M. Hatakenaka, K. Takayama et al., “Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging,” *Radiology*, vol. 261, no. 2, pp. 598–604, 2011.

[25] C. Reischauer, J. M. Froehlich, D.-M. Koh et al., “Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps—initial observations,” *Radiology*, vol. 257, no. 2, pp. 523–531, 2010.

[26] Q. Chang, N. Wu, H. Ouyang, and Y. Huang, “Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy,” *Clinical Imaging*, vol. 36, no. 2, pp. 98–103, 2012.

[27] R. Zhou, T. Yu, C. Feng et al., “Diffusion-weighted imaging for assessment of lung cancer response to chemotherapy,” *Chinese Journal of Lung Cancer*, vol. 14, no. 3, pp. 256–260, 2011.

[28] A. Dzik-Jurasz, C. Domenig, M. George et al., “Diffusion MRI for prediction of response of rectal cancer to chemoradiation,” *The Lancet*, vol. 360, no. 9329, pp. 307–308, 2002.

[29] A. M. Herneth, S. Guccione, and M. Bednarski, “Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization,” *European Journal of Radiology*, vol. 45, no. 3, pp. 208–213, 2003.